2014 年塞拉利昂接受法匹拉韦（T-705）治疗的埃博拉病毒病患者的临床和病毒学特征。

Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014.

机构信息

No. 307 Hospital.

No. 302 Hospital, Beijing, China.

出版信息

Clin Infect Dis. 2016 Nov 15;63(10):1288-1294. doi: 10.1093/cid/ciw571. Epub 2016 Aug 23.

DOI:10.1093/cid/ciw571

PMID:27553371

Abstract

BACKGROUND

During 2014-2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently.

METHODS

A retrospective clinical case series was performed for EVD patients in Sierra Leone-China Friendship Hospital. Patients with confirmed EVD were sequentially enrolled and treated with either World Health Organization (WHO)-recommended supportive therapy (control group) from 10 to 30 October, or treated with WHO-recommended therapy plus favipiravir (T-705) from 1 to 10 November 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.

RESULTS

The overall survival rate in the T-705 treatment group was higher than that of the control group (56.4% [22/39] vs 35.3% [30/85]; P = .027). Among the 35 patients who finished all designed endpoint observations, the survival rate in the T-705 treatment group (64.8% [11/17]) was higher than that of the control group (27.8% [5/18]). Furthermore, the average survival time of the treatment group (46.9 ± 5.6 days) was longer than that of the control group (28.9 ± 4.7 days). Most symptoms of patients in the treatment group improved significantly. Additionally, 52.9% of patients who received T-705 had a >100-fold viral load reduction, compared with only 16.7% of patients in the control group.

CONCLUSIONS

Treatment of EVD with T-705 was associated with prolonged survival and markedly reduced viral load, which makes a compelling case for further randomized controlled trials of T-705 for treating EVD.

摘要

背景

2014-2015 年期间，埃博拉病毒病（EVD）在西非部分地区爆发。目前尚无针对 EVD 的批准抗病毒药物。

方法

对塞拉利昂-中国友好医院的 EVD 患者进行了回顾性临床病例系列研究。连续纳入确诊为 EVD 的患者，并于 2014 年 10 月 10 日至 30 日接受世界卫生组织（WHO）推荐的支持性治疗（对照组），或于 11 月 1 日至 10 日接受 WHO 推荐的治疗加法匹拉韦（T-705）治疗。观察对照组 85 例和 T-705 治疗组 39 例患者的生存和病毒学特征。

结果

T-705 治疗组的总生存率高于对照组（56.4%[22/39]比 35.3%[30/85]；P=0.027）。在完成所有设计终点观察的 35 例患者中，T-705 治疗组（64.8%[11/17]）的生存率高于对照组（27.8%[5/18]）。此外，治疗组的平均生存时间（46.9±5.6 天）长于对照组（28.9±4.7 天）。治疗组患者的大多数症状明显改善。此外，接受 T-705 治疗的患者中有 52.9%的病毒载量下降超过 100 倍，而对照组仅有 16.7%。